325 related articles for article (PubMed ID: 24037724)
1. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.
Schmidt-Hieber M; Labopin M; Beelen D; Volin L; Ehninger G; Finke J; Socié G; Schwerdtfeger R; Kröger N; Ganser A; Niederwieser D; Polge E; Blau IW; Mohty M
Blood; 2013 Nov; 122(19):3359-64. PubMed ID: 24037724
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
[TBL] [Abstract][Full Text] [Related]
4. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
[TBL] [Abstract][Full Text] [Related]
6. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
Green ML; Leisenring WM; Xie H; Walter RB; Mielcarek M; Sandmaier BM; Riddell SR; Boeckh M
Blood; 2013 Aug; 122(7):1316-24. PubMed ID: 23744585
[TBL] [Abstract][Full Text] [Related]
7. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
Nachbaur D; Clausen J; Kircher B
Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
[TBL] [Abstract][Full Text] [Related]
8. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Schafhausen P; Jaburg N; Löliger C; Schäfer P; Hinke A; Zander AR
Br J Haematol; 2001 Jun; 113(4):1060-71. PubMed ID: 11442503
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
[TBL] [Abstract][Full Text] [Related]
10. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.
Behrendt CE; Rosenthal J; Bolotin E; Nakamura R; Zaia J; Forman SJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1):54-60. PubMed ID: 19135943
[TBL] [Abstract][Full Text] [Related]
11. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
12. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.
Itonaga H; Taguchi J; Fukushima T; Tsushima H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; Onimaru Y; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Honda S; Miyazaki Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):607-15. PubMed ID: 23333533
[TBL] [Abstract][Full Text] [Related]
13. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
[TBL] [Abstract][Full Text] [Related]
14. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.
Lin CH; Su YJ; Hsu CY; Wang PN; Teng CJ
Transpl Infect Dis; 2019 Aug; 21(4):e13096. PubMed ID: 31004545
[TBL] [Abstract][Full Text] [Related]
15. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.
Jang JE; Kim SJ; Cheong JW; Hyun SY; Kim YD; Kim YR; Kim JS; Min YH
Ann Hematol; 2015 Feb; 94(2):275-82. PubMed ID: 25135450
[TBL] [Abstract][Full Text] [Related]
16. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
Mariotti J; Maura F; Spina F; Roncari L; Dodero A; Farina L; Montefusco V; Carniti C; Sarina B; Patriarca F; Rambaldi A; Onida F; Olivieri A; Zallio F; Corradini P
Biol Blood Marrow Transplant; 2014 Jun; 20(6):885-90. PubMed ID: 24583412
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
18. Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
Ramanathan M; Teira P; Battiwalla M; Barrett J; Ahn KW; Chen M; Green J; Laughlin M; Lazarus HM; Marks D; Saad A; Seftel M; Saber W; Savani B; Waller EK; Wingard J; Auletta JJ; Lindemans CA; Boeckh M; Riches ML
Bone Marrow Transplant; 2016 Aug; 51(8):1113-20. PubMed ID: 27042847
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
20. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
